<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">akusherstvo</journal-id><journal-title-group><journal-title xml:lang="en">Obstetrics, Gynecology and Reproduction</journal-title><trans-title-group xml:lang="ru"><trans-title>Акушерство, Гинекология и Репродукция</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2313-7347</issn><issn pub-type="epub">2500-3194</issn><publisher><publisher-name>IRBIS LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17749/2313-7347/ob.gyn.rep.2021.202</article-id><article-id custom-type="elpub" pub-id-type="custom">akusherstvo-968</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group></article-categories><title-group><article-title>Risks of cerebrovascular disorders associated with combined hormonal contraceptives</article-title><trans-title-group xml:lang="ru"><trans-title>Риски развития нарушений мозгового кровообращения при использовании комбинированных гормональных контрацептивов</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0590-8483</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Новосартян</surname><given-names>М. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Novosartyan</surname><given-names>M. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Новосартян Маргарита Геннадиевна – аспирант кафедры акушерства, гинекологии и перинатологии </p><p>350063 Краснодар, ул. Митрофана Седина, д. 4</p></bio><bio xml:lang="en"><p>Margarita G. Novosartyan – MD, Postgraduate Student, Department of Obstetrics, Gynecology and Perinatology</p><p>4 Mitrofana Sedina Str., Krasnodar 350063</p></bio><email xlink:type="simple">novosartyan89@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Кубанский государственный медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kuban State Medical University, Health Ministry of Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>04</day><month>05</month><year>2021</year></pub-date><volume>15</volume><issue>2</issue><fpage>143</fpage><lpage>155</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Novosartyan M.G., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Новосартян М.Г.</copyright-holder><copyright-holder xml:lang="en">Novosartyan M.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.gynecology.su/jour/article/view/968">https://www.gynecology.su/jour/article/view/968</self-uri><abstract><sec><title>Introduction</title><p>Introduction. Cerebral circulation disorders (CCD) hold the third place in the structure of complications coupled to combined oral contraceptives (СОСs). Acute disturbance of the cerebral blood supply is the main etiological factor for such complication; and hidden predisposition to thrombotic conditions such as thrombophilia plays a pivotal role in its pathogenesis, which is manifested due to administered hormonal contraceptives.</p></sec><sec><title>Aim</title><p>Aim: to assess rate of detected genetic thrombophilic hemostatic defects, congenital and acquired ADAMTS-13 deficiency, antiphospholipid antibodies (APA), antibodies to phospholipid cofactors, hyperhomocysteinemia in patients with CCD administered with СОСs.</p></sec><sec><title>Materials and Methods</title><p>Materials and Methods. A prospective analysis of 89 COCs use cases in women of reproductive age was carried out, among which 60 cases were selected for this study satisfying to the inclusion and exclusion criteria. Group I consisted of 30 patients manifested with various CCD types due to COCs use, group II – 30 women taking COCs for at least 1 year lacking any thrombotic complications.</p></sec><sec><title>Results</title><p>Results. Women administered with COCs are at the peak CCD risk within the first 2 months after the onset. Somatic diseases differed little in patients from groups I and II. In group I, 5 (41.7 %) patients with venous thrombosis did not have classical thrombophilia, but 4 (33.3 %) women had anti-ADAMTS-13 antibodies combined with elevated von Willebrand factor (vWF) level. Inherited thrombophilia was less prevalent in patients with arterial thrombosis and transient ischemic attack (TIA): 1 (5.5 %) case of Leiden factor V mutation compared to patients with venous blood flow disorders (p &lt; 0.05). Such patients more frequently had criterial APA (61.1 %), so that 5 (27.8 %) patients were found to have more than one type of criterial APA. In 4 (22.2 %) cases these were patients with ischemic stroke, 3 (37.5 %) of which had combination of three criterial APA (triple positivity) and 1 (12.5 %) had two criterial APA (double positivity); among them detection rate of criterial APA was 50.0 %. One patient (double positivity) was with TIA.</p></sec><sec><title>Conclusion</title><p>Conclusion. It was found that: i) genetic and acquired factors were identified at high rate in patients with CCD administered with COCs, contributing to coagulopathy (86.7 %); ii) in case of venous thrombotic CCD coupled to administered COCs, inherited thrombophilia (58.3 %) prevails, in arterial thrombosis – APA circulation (50.0 %); iii) etiopathogenetic role of APA circulation in impaired cerebral blood flow depends on antibody type (criterial APA) and titer; iv) preexisting hypercoagulability leading to CCD coupled to COCs may be linked to several thrombophilic defects unrelated to classical thrombophilia.</p></sec></abstract><trans-abstract xml:lang="ru"><sec><title>Введение</title><p>Введение. Нарушения мозгового кровообращения (НМК) занимают третье место в структуре осложнений приема комбинированных оральных контрацептивов (КОК). В этиопатогенезе данного осложнения немаловажную роль играет скрытая предрасположенность к тромботическим состояниям – тромбофилия, которая реализуется в условиях применения гормональных контрацептивов.</p></sec><sec><title>Цель исследования</title><p>Цель исследования: устaнoвить чaстoту выявлeния генетических тромбофилических дефектов системы гемостаза, вpoждeннoгo и пpиoбpeтeннoгo дeфицитa ADAMTS-13, aнтифoсфoлипидных aнтитeл (AФA), aнтитeл к кoфaктopaм фoсфoлипидoв и гипepгoмoцистeинeмии у пaциeнтoк с НМК нa фoнe пpиeмa КОК.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Проведен проспективный анализ 89 случаев применения КОК среди женщин репродуктивного возраста. Из них для исследования были отобраны 60 случаев, удовлетворяющих применяемым критериям включения и исключения. Группу I составили 30 пациенток, у кoтopых нa фoнe пpиeмa КОК имeли мeстo paзличныe вapиaнты НМК, группу II – 30 пациенток, пpимeнявших КОК в тeчeниe нe мeнee 1 гoдa бeз тpoмбoтичeских oслoжнeний.</p></sec><sec><title>Результаты</title><p>Результаты. Нaибoльший pиск НМК нa фoнe пpиeмa КОК пpeдстaвляют пepвыe 2 мeс oт нaчaлa пpимeнeния. Сoмaтичeскиe зaбoлeвaния мaлo различaлись у пaциeнтoк гpупп I и II. В группе I у 5 из 12 (41,7 %) пaциeнтoк с вeнoзным тpoмбoзoм нe былo клaссичeскoй тpoмбoфилии, однако у 4 (33,3 %) жeнщин были выявлены aнтитeла к ADAMTS-13 в сoчeтaнии с пoвышeнием фактора фон Виллебранда (vWF). У пациенток с артериальным тромбозом и преходящими НМК (ПНМК) генетическая тромбофилия выявлялась реже: 1 (5,5 %) случай мутации фактора V Leiden в сравнении с пациентками, имевшими нарушения венозного кровотока (p &lt; 0,05). У этой категории пациенток чаще выявлялись критериальные АФА (61,1 %), причем у 5 (27,8 %) пациенток было определено более одного вида критериальных АФА. В 4 (22,2 %) случаях это были пациентки с ишемическим инсультом, у 3 (37,5 %) из которых обнаружено сочетание трех критериальных АФА (triple positivity) и у 1 (12,5 %) – двух АФА (double positivity); процент выявления критериальных АФА среди них составил 50,0 %. Одна пациентка (double positivity) была с ПНМК.</p></sec><sec><title>Заключение</title><p>Заключение. Во-первых, у пациенток с НМК при применении КОК в высоком проценте присутствуют генетические и приобретенные факторы, способствующие коагулопатии (86,7 %); во-вторых, при венозных тромбозах на фоне КОК преобладает генетическая тромбофилия (58,3 %), при артериальных тромбозах – циркуляция АФА (50,0 %); в-третьих, этиопатогенетическая роль циркуляции АФА в нарушении мозгового кровотока зависит от вида антител (критериальные АФА) и их титра; в четвертых, предсуществующая гиперкоагуляция, ведущая к НМК при использовании КОК, может быть связана с присутствием нескольких тромбофилических дефектов, не относящихся к классической тромбофилии.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>комбинированные оральные контрацептивы</kwd><kwd>КОК</kwd><kwd>нарушения мозгового кровообращения</kwd><kwd>НМК</kwd><kwd>генетическая тромбофилия</kwd><kwd>тромботические осложнения</kwd><kwd>антикоагулянтная терапия</kwd><kwd>нарушения системы гемостаза</kwd></kwd-group><kwd-group xml:lang="en"><kwd>combined oral contraceptives</kwd><kwd>СОСs</kwd><kwd>cerebral circulation disorders</kwd><kwd>CCD</kwd><kwd>genetic thrombophilia</kwd><kwd>thrombotic complications</kwd><kwd>anticoagulant therapy</kwd><kwd>hemostasis disorders</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Arnett D.K., Blumenthal R.S., Albert M.A. et al. 2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596–e646. https://doi.org/10.1161/CIR.0000000000000678.</mixed-citation><mixed-citation xml:lang="en">Arnett D.K., Blumenthal R.S., Albert M.A. et al. 2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596–e646. https://doi.org/10.1161/CIR.0000000000000678.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Champaloux S.W., Tepper N.K., Monsour M. et al. Use of combined hormonal contraceptives among women with migraines and risk of ischemic stroke. Am J Obstet Gynecol. 2017;16(5):489.e1–489.e7. https://doi.org/10.1016/j.ajog.2016.12.019.</mixed-citation><mixed-citation xml:lang="en">Champaloux S.W., Tepper N.K., Monsour M. et al. Use of combined hormonal contraceptives among women with migraines and risk of ischemic stroke. Am J Obstet Gynecol. 2017;16(5):489.e1–489.e7. https://doi.org/10.1016/j.ajog.2016.12.019.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Denorme F., Kraft P., Pareyn I. et al. Reduced ADAMTS13 levels in patients with acute and chronic cerebrovascular disease. PLoS One. 2017;12(6):e0179258. https://doi.org/10.1371/journal.pone.0179258.</mixed-citation><mixed-citation xml:lang="en">Denorme F., Kraft P., Pareyn I. et al. Reduced ADAMTS13 levels in patients with acute and chronic cerebrovascular disease. PLoS One. 2017;12(6):e0179258. https://doi.org/10.1371/journal.pone.0179258.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Dhont М. History of oral hormonal contraception. Eur J Contracept Reprod Health Care. 2010;15(Suppl 2):S12–8. https://doi.org/10.3109/13625187.2010.513071.</mixed-citation><mixed-citation xml:lang="en">Dhont М. History of oral hormonal contraception. Eur J Contracept Reprod Health Care. 2010;15(Suppl 2):S12–8. https://doi.org/10.3109/13625187.2010.513071.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Hugon-Rodin J., Horellou M., Conard J. et al. Combined hormonal contraceptives and first venous thrombosis in young french women: impact of thrombotic family history. J Endocr Soc. 2017;1(6):762–71. https://doi.org/10.1210/js.2017-00090.</mixed-citation><mixed-citation xml:lang="en">Hugon-Rodin J., Horellou M., Conard J. et al. Combined hormonal contraceptives and first venous thrombosis in young french women: impact of thrombotic family history. J Endocr Soc. 2017;1(6):762–71. https://doi.org/10.1210/js.2017-00090.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Isiadinso I, Wenger NK. Do we need a different approach to assess cardiovascular risk in women? US Cardiol Rev. 2017;11:5–9. https://doi.org/10.15420/usc.2016:8:2.</mixed-citation><mixed-citation xml:lang="en">Isiadinso I, Wenger NK. Do we need a different approach to assess cardiovascular risk in women? US Cardiol Rev. 2017;11:5–9. https://doi.org/10.15420/usc.2016:8:2.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Lidegaard Ø., Edström B., Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception. 2002;65(3):187–96. https://doi.org/10.1016/s0010-7824(98)00033-x.</mixed-citation><mixed-citation xml:lang="en">Lidegaard Ø., Edström B., Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception. 2002;65(3):187–96. https://doi.org/10.1016/s0010-7824(98)00033-x.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Карахалис Л.Ю., Федорович О.К. Дифференцированное применение комбинированных пероральных контрацептивов. Акушерство и гинекология. 2006;(6):51–4.</mixed-citation><mixed-citation xml:lang="en">Karakhalis L.Yu., Fedorovich O.K. Differential use of combined oral contraceptives. [Differencirovannoe primenenie kombinirovannyh peroral'nyh kontraceptivov]. Akusherstvo i ginekologiya. 2006;(6):51–4. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Макацария А.Д., Дадак К., Бицадзе В.О. и др. Клинические особенности у пациенток с гормонально-зависимыми состояниями и дефицитом магния. Акушерство и гинекология. 2017;(5):124–31. https://doi.org/10.18565/aig.2017.5.124-131.</mixed-citation><mixed-citation xml:lang="en">Makatsariya A.D., Dadak K., Bitsadze V.O. et al. Clinical features in patients with hormone-dependent conditions and magnesium deficiency. [Klinicheskie osobennosti u pacientok s gormonal'no-zavisimymi sostoyaniyami i deficitom magniya]. Akusherstvo i ginekologiya. 2017;(5):124–31. (In Russ.). https://doi.org/10.18565/aig.2017.5.124-131.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Trenor C.C., Chung R.J., Michelson A.D. et al. Hormonal contraception and thrombotic risk: a multidisciplinary approach. Pediatrics. 2011;127(2):347–57. https://doi.org/10.1542/peds.2010-2221.</mixed-citation><mixed-citation xml:lang="en">Trenor C.C., Chung R.J., Michelson A.D. et al. Hormonal contraception and thrombotic risk: a multidisciplinary approach. Pediatrics. 2011;127(2):347– 57. https://doi.org/10.1542/peds.2010-2221.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Карахалис Л.Ю. Персонифицированный выбор гормональной контрацепции. Гинекология. 2018;20(4):52–4. https://doi.org/10.26442/20795696_2018.4.52-54.</mixed-citation><mixed-citation xml:lang="en">Karakhalis L.Yu. Personified choice of hormonal contraception. [Personificirovannyj vybor gormonal'noj kontracepcii]. Ginekologiya. 2018;20(4):52–4. (In Russ.). https://doi.org/10.26442/20795696_2018.4.52-54.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Карахалис Л.Ю., Папова Н.С., Майорова А.В. Лечение генитального эндометриоза гормональными контрацептивами. Медицинский совет. 2016;(2):6–11. https://doi.org/10.21518/2079-701X-2016-2-6-11.</mixed-citation><mixed-citation xml:lang="en">Karakhalis L.Yu., Papova N.S., Mayorova A.V. Treating endometriosis with hormonal contraceptives. [Lechenie genital'nogo endometrioza gormonal'nymi kontraceptivami]. Medicinskij sovet. 2016;(2):6–11. (In Russ.). https://doi.org/10.21518/2079-701X-2016-2-6-11.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Макацария А.Д., Бицадзе В.О., Акиньшина С.В. Тромбозы и тромбоэмболии в акушерско-гинекологической клинике. M.: МИА, 2007. 1064 с.</mixed-citation><mixed-citation xml:lang="en">Makatsariya A.D., Bitsadze V.O., Akinshina S.V. Thrombosis and thromboembolism in the obstetric-пynecological clinic. [Trombozy i tromboembolii v akushersko-ginekologicheskoj klinike]. Moscow: MIA, 2007. 1064 p. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Baart S.J., Dam V., Scheres L.J.J. et al.; CREW consortium. Cardiovascular risk prediction models for women in the general population: A systematic review. PLoS One. 2019;14(1):e0210329. https://doi.org/10.1371/journal.pone.0210329.</mixed-citation><mixed-citation xml:lang="en">Baart S.J., Dam V., Scheres L.J.J. et al.; CREW consortium. Cardiovascular risk prediction models for women in the general population: A systematic review. PLoS One. 2019;14(1):e0210329. https://doi.org/10.1371/journal.pone.0210329.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Lloyd-Jones D.M., Hong Y., Labarthe D. et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association’s Strategic Impact Goal through 2020 and beyond. Circulation. 2010;121(4):586–61. https://doi.org/10.1161/CIRCULATIONAHA.109.192703.</mixed-citation><mixed-citation xml:lang="en">Lloyd-Jones D.M., Hong Y., Labarthe D. et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association’s Strategic Impact Goal through 2020 and beyond. Circulation. 2010;121(4):586–61. https://doi.org/10.1161/CIRCULATIONAHA.109.192703.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Carlton C., Banks M., Sundararajan S. Oral contraceptives and ischemic stroke risk. Stroke. 2018;49(4):e157–e159. https://doi.org/10.1161/STROKEAHA.117.020084;</mixed-citation><mixed-citation xml:lang="en">Carlton C., Banks M., Sundararajan S. Oral contraceptives and ischemic stroke risk. Stroke. 2018;49(4):e157–e159. https://doi.org/10.1161/STROKEAHA.117.020084;</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Блинов Д.В., Ушакова Т.И., Макацария А.Д. и др. Гормональная конфацепция и дефицит магния: результаты субанализа исследования MAGYN. Акушерство, Гинекология и Репродукция. 2017;11(1):36– 48. https://doi.org/10.17749/2313-7347.2017.11.1.036-048.</mixed-citation><mixed-citation xml:lang="en">Blinov D.V., Ushakova T.I., Makatsariya N.A. et al. Hormonal confusion and magnesium deficiency: a subanalysis of the MAGYN study. [Gormonal'naya kontracepciya i deficit magniya: rezul'taty subanaliza issledovaniya MAGYN]. Akusherstvo, Ginekologia i Reprodukcia. 2017;11(1):36–48. (In Russ.). https://doi.org/10.17749/2313-7347.2017.11.1.036-048.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Gourdy P., Bachelot A., Catteau-Jonard S. et al. Hormonal contraception in women at risk of vascular and metabolic disorders: guidelines of the French Society of Endocrinology. Ann Endocrinol (Paris). 2012;73(5):469–87. https://doi.org/10.1016/j.ando.2012.09.001.</mixed-citation><mixed-citation xml:lang="en">Gourdy P., Bachelot A., Catteau-Jonard S. et al. Hormonal contraception in women at risk of vascular and metabolic disorders: guidelines of the French Society of Endocrinology. Ann Endocrinol (Paris). 2012;73(5):469–87. https://doi.org/10.1016/j.ando.2012.09.001.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Belbasis L., Savvidou M.D., Kanu C. et al. Birth weight in relation to health and disease in later life: an umbrella review of systematic reviews and meta-analyses. BMC Med. 2016;14(1):147. https://doi.org/10.1186/s12916-016-0692-5.</mixed-citation><mixed-citation xml:lang="en">Belbasis L., Savvidou M.D., Kanu C. et al. Birth weight in relation to health and disease in later life: an umbrella review of systematic reviews and metaanalyses. BMC Med. 2016;14(1):147. https://doi.org/10.1186/s12916-0160692-5.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Timmis A., Townsend N., Gale C.P. et al.; European Society of Cardiology. European Society of Cardiology: Cardiovascular Disease Statistics 2019. Eur Heart J. 2020;41(1):12–85. https://doi.org/10.1093/eurheartj/ehz859.</mixed-citation><mixed-citation xml:lang="en">Timmis A., Townsend N., Gale C.P. et al.; European Society of Cardiology. European Society of Cardiology: Cardiovascular Disease Statistics 2019. Eur Heart J. 2020;41(1):12–85. https://doi.org/10.1093/eurheartj/ehz859.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Сукoнцeвa Т.A., Кaплинa O.Ю. К вoпpoсу o пaтoгeнeзe тpoмбoзoв пpи aнтифoсфoлипиднoм синдpoмe. Aкушepствo, Гинекология и Репродукция. 2018;12(3):72–8. https://doi.org/10.17749/2313-7347.2018.12.3.072-078.</mixed-citation><mixed-citation xml:lang="en">Sukontseva T.A., Kaplina O.Yu. On the pathogenesis of thromboses in antiphospholipid syndrome. [K vopposu o patogeneze tpombozov ppi antifosfolipidnom sindpome]. Akusherstvo, Ginekologia i Reprodukcia. 2018;12(3):72–8. (In Russ.). https://doi.org/10.17749/23137347.2018.12.3.072-078.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Макацария А.Д., Саидова Р.А. Гормональная контрацепция и тромбофилические состояния. M.: Триада-Х, 2004. 240 с.</mixed-citation><mixed-citation xml:lang="en">Makatsariya A.D., Saidova R.A. Hormonal contraception and thrombophilic conditions. [Gormonal'naya kontracepciya i trombofilicheskie sostoyaniya]. Moscow: Triada-X, 2004. 240 p. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Rott H. Birth control pills and thrombotic risks: differences of contraception methods with and without estrogen. Hamostaseologie 2019;39(1):42–8. https://doi.org/10.1055/s-0039-1677806.</mixed-citation><mixed-citation xml:lang="en">Rott H. Birth control pills and thrombotic risks: differences of contraception methods with and without estrogen. Hamostaseologie. 2019;39(1):42–8. https://doi.org/10.1055/s-0039-1677806.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Proia K.K., Thota A.B., Njie G.J. et al. Team-based care and improved blood pressure control: a community guide systematic review. Am J Prev Med. 2014;47:86–99. https://doi.org/10.1016/j.amepre.2014.03.004.</mixed-citation><mixed-citation xml:lang="en">Proia K.K., Thota A.B., Njie G.J. et al. Team-based care and improved blood pressure control: a community guide systematic review. Am J Prev Med. 2014;47:86–99. https://doi.org/10.1016/j.amepre.2014.03.004.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Хамани Н.М., Саидова Р.А., Хамани И.В. и др. Ретроспективный анализ факторов риска тромботических осложнений при приеме комбинированных оральных контрацептивов. Акушерство и гинекология. 2019;(6):108–14. https://doi.org/10.18565/aig.2019.6.108-114.</mixed-citation><mixed-citation xml:lang="en">Khamani N.M., Saidova R.A., Khamani I.V. et al. Retrospective analysis of risk factors for thrombotic events due to the use of combined oral contraceptives. [Retrospektivnyj analiz faktorov riska tromboticheskih oslozhnenij pri prieme kombinirovannyh oral'nyh kontraceptivov]. Akusherstvo i ginekologiya. 2019;(6):108–14. (In Russ.). https://doi.org/10.18565/aig.2019.6.108-114.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Мeдицинскиe кpитepии пpиeмлeмoсти для испoльзoвaния мeтoдoв кoнтpaцeпции. 5-e изд. Жeнeвa: ВOЗ, 2015. 192 с. Peжим дoступa: http://www.euro.who.int/data/assets/pdf_file/0005/348116/MEC-merged.pdf.</mixed-citation><mixed-citation xml:lang="en">Medical Acceptance Criteria for Methods of Contraception. 5th ed. Translated from English by the Europe WHO Regional Office. [Medicinskie kritepii priemlemosti dlya ispol'zovaniya metodov kontracepcii. 5-e izd. Perevod s anglijskogo osushchestvlen Evropejskim regional'nym byuro VOZ]. Zheneva: VOZ, 2015. 192 p. (In Russ.). Available at: http://www.euro.who.int/data/assets/pdf_file/0005/348116/MEC-merged.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Тромбогеморрагические осложнения в акушерско-гинекологической практике. Руководство для врачей. Под ред. А.Д. Макарация. M.: МИА, 2011. 1050 с.</mixed-citation><mixed-citation xml:lang="en">Thrombohemorrhagic complications in obstetric and gynecological practice: a guideline for doctors. [Trombogemorragicheskie oslozhneniya v akushersko-ginekologicheskoj praktike. Rukovodstvo dlya vrachej. Pod red. A.D. Makatsariya]. Moscow: MIA, 2011. 1050 p. (In Russ.).</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
